James P. Scanlan, Attorney at Law

Home Page

Curriculum Vitae

Publications

Published Articles

Conference Presentations

Working Papers

Journal Comments

Truth in Justice Articles

Measuring Health Disp

Outline and Guide to MHD

Summary to MHD

Solutions

Solutions Database

Irreducible Minimums

Pay for Performance

Between Group Variance

Concentration Index

Gini Coefficient

Reporting Heterogeneity

Cohort Considerations

Relative v Absolute Diff

NHDR Technical Issues

MHD A Articles

MHD B Conf Presentations

MHD D Journal Comments

Consensus/Non-Consensus

Institutional Corresp

Scanlan's Rule

Outline and Guide to SR

Summary to SR

Semantic Issues

Employment Tests

Case Study

Case Study Answers

Subgroup Effects

Illogical Premises

Illogical Premises II

Inevitable Interaction

Feminization of Poverty S

Explanatory Theories

Mortality and Survival

Immunization Disparities

Truncation Issues

Collected Illustrations

Income Illustrations

Framingham Illustrations

Life Table Illustrations

NHANES Illustrations

Credit Score Illustration

Representational Disp

Statistical Signif SR

Comparing Averages

Meta-Analysis

Case Control Studies

Mortality and Survival 2

Measures of Association

Educational Disparities

Nuclear Deterrence

Employment Discrimination

Job Segregation

Measuring Hiring Discr

Disparate Impact

Four-Fifths Rule

Lending Disparities

Disparities - High Income

Underadjustment Issues

Lathern v. NationsBank

Holder/Perez Letter

Discipline Disparities

Disparate Treatment

Los Angeles SWPBS

Suburban Disparities

Disabilities - PL 108-446

NEPC Colorado Study

NEPC National Study

Duncan/Ali Letter

Feminization of Poverty

Affirmative Action

Affirm Action for Women

Other Affirm Action

Justice John Paul Stevens

Statistical Reasoning

The Sears Case

The AT&T Consent Decree

Cross v. ASPI

Vignettes

Times Higher Issues

Gender Diff in DADT Term

Adjustment Issues

Percentage Points

Odds Ratios

Statistical Signif Vig

Journalists & Statistics

Prosecutorial Misconduct

Outline and Guide

Misconduct Summary

B1 Agent Cain Testimony

B1a Bev Wilsh Diversion

B2 Bk Entry re Cain Call

B3 John Mitchell Count

B3a Obscuring Msg Slips

B3b Missing Barksdale Int

B4 Park Towers

B5 Dean 1997 Motion

B6 Demery Testimony

B7 Sankin Receipts

B7a Sankin HBS App

B8 DOJ Complicity

B9 Doc Manager Complaints

B9a Fabricated Gov Exh 25

B11a DC Bar Complaint

Letters (Misconduct)

Links Page

Misconduct Profiles

Arlin M. Adams

Jo Ann Harris

Bruce C. Swartz

Swartz Addendum 2

Swartz Addendum 3

Swartz Addendum 4

Swartz Addendum 7

Robert E. O'Neill

O'Neill Addendum 7

Paula A. Sweeney

Robert J. Meyer

Lantos Hearings

Password Protected

OIC Doc Manager Material

DC Bar Materials

Temp Confidential

DV Issues

Document Storage

Pre 1989

1989 - present

Presentations

Prosec Misc Docs

Prosec Misc Docs II

Profile PDFs

Misc Letters July 2008 on

Large Prosec Misc Docs

HUD Documents

Transcripts

Miscellaneous Documents

Unpublished Papers

Letters re MHD

Tables

MHD Comments

Figures

ASPI Documents

Web Page PDFs

Pages Transfer


Deficiencies of Case Control Studies

(September 30, 2010)

 

[This page remains a sketch.  It was hurriedly created mainly to provide a reference for a planned comment on Sedgwick P.  Statistical Question: Confounding in case control studies. BMJ 2010; 341:c5136.]   

 

The case control study is provides a seemingly efficient means of determining strengths of association from a small sample.  The following table is based on data from a 1993 American Journal of Public Health article addressing the association between hair dry and cancer.

 

Date from Case Control Study of Effects of Hair Dies on Risk of Cancer

Factor

Nature

Cases

Controls

N

Dye

159

619

Y

Dye

14

31

 

The table indicates that from 14 of 173 persons with cancer (cases) used hair dye compared with 31 of 650 persons without cancer (controls).  From this one can determine either (a) that the ratio of the odds that a person with cancer used dye to the odds that a person without cancer used dye or (b) that the ratio of the odds that a person using dye had cancer to the odds that a person not using dye had cancer is 1.76. 

 

In cases where the adverse outcome is rather rare (i.e., cases are rare), (b) would approximate the relative risk of cancer for those using dye compared with those not using dye (which we could illustrate by multiplying both the dyers and non-dyers among the controls by 1000).  The more common the outcome, the greater will be the odds ratio compared with the relative risk.  For example, if the persons in the study reflected the entire universe (which would mean a rather high cancer rate), the relative risk would be only 1.52.

 

There is a larger problem with case control study than the failure of the odds ratio to approximate the relative risk.  Such problem lies in the fact that the relative risk, being influenced by overall prevalence, is not a useful indicator of the strength of association.  In order to determine the strengths of association one must have the actual outcome rates, as discussed in the Subgroup Effects page of the Scanlan’s Rule page.  See also recent references 1 and 2.  But in a case control study, while it may be possible to know the relative risk (or something close to it), the actual rates are not known.

 

The problem is similar to that addressed in the Representational Disparities sub-page of the Scanlan’s Rule page, an illustration of which is found on the Gender differences in DODT sub-page of the Vignettes.

 

References:

 

1. Problems in identifying interaction where groups have different base rates.  BMJ  Sept. 21, 2010 (responding to Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ 2003;326:219): http://www.bmj.com/content/326/7382/219/reply#bmj_el_241943

 

2. Rethinking the premises of subgroup analyses. BMJ June 7, 2010 (responding to Sun X, Briel M. Walter SD, and Guyatt GH.  Is as subgroup effect believable? Updating criteria to evaluated the credibility of subgroup analyses. BMJ 2010;340:850-854): http://www.bmj.com/cgi/eletters/340/mar30_3/c117